Novo Nordisk's Karsten Munk Knudsen is targeting 800 million obese people globally.

Novo Nordisk's CEO said on Wednesday side-effects were not a problem in the trial of its next-generation obesity drug ...

KEY TAKEAWAYS Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's ...

Novo Nordisk, maker of the weight-loss drug Wegovy, faces potential challenges as U.S. President Trump threatens tariffs on ...

Novo Nordisk's next-gen obesity drug, CagriSema, faces trial challenges with dosage flexibility and trial length as side-effects remain controlled. Investor skepticism arose from weaker-than-expected ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t ...

Sales of Wegovy, a prescription weight loss injection, surged to 19.9 billion Danish kroner (£2.2 billion) in the fourth ...

Novo Nordisk expects sales growth to slow this year as capacity constraints, intensifying competition and pricing pressure drag on sales of its blockbuster weight-loss and diabetes drugs. The Danish ...

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of ...

Ozempic, which accounts for 41% of the company's sales, is an injectable anti-diabetic treatment that became wildly popular ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.